Your Journey
Cancer Types
Advocacy Partner News
Conferences
INFORMATION BY CANCER TYPE
Myelodysplastic syndrome
Sometimes we can be regarded as being obsessed with cancer, but every single cancer survivor is more than that, and hold important roles in our lives to play.
In an interview with CURE Mesa, director, UT Health San Antonio Cancer Center, shed light on these recent updates in PV and ET, and discussed the proper therapeutic management of these diseases.
For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.
Cancer survivors generally work very hard to be healthy after a diagnosis. This article gives permission to enjoy life and have a balanced attitude toward healthy living.
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
How one cancer survivor attempts to cope with the reality of having chemo for the rest of her life.
An acute myeloid leukemia survivor shares her insight on raising 3 kids while fighting for her life.
Researchers are identifying targets to treat chronic lymphocytic leukemia.
Injured DNA can hide damaged blood cells in myelodysplastic syndrome (MDS).
The FDA has approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML).
Special Feature
Talk about this article with other patients, caregivers, and advocates in the Myelodysplastic-syndrome CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Myelodysplastic Syndromes Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of myelodysplastic syndromes.
Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)
Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.
Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.
